Phase II trial Combining Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer

Dr. Yang-Min Ning and collaborators reported, in the April 20, 2010 issue of the Journal of Clinical Oncology, a Phase II trial which combined chemotherapy (docetaxel) with an anti-angiogenesis drug for men with castration-resistant prostate cancer (CRPC). The data suggests that such a combination is more effective than chemotherapy alone. […]

Lenalidomide in Combination with Docetaxel to Treat Advanced Prostate Cancer

More from my explorations at the American Association of Cancer Researchers (AACR) conference in Washington, D.C. Abstract 5386 described a study using a thalidomide analogue called lenalidomide (Revlimid), in combination with Taxotere, which currently is the only approved drug for chemotherapy for advanced, metastatic castrate resistant prostate cancer. […]

Chemotherapy, Combining Drugs to Extend Life

The continuing search for effective treatments for men with hormone refractory prostate cancer (HRPC) has been a long and not very successful story. To date, under scientific conditions, the only chemotherapy which has demonstrated any survival benefit for men with prostate cancer has been docetaxel with prednisone. However, the survival benefit is very limited, only [...]


According to a randomized study run and reported by William D.Figg, PharmD, head of the Molecular Pharmacology Section of the Centerfor Cancer Research at the National Cancer Institute, in Bethesda, MD. And published online January 23, 2009 in the Journal of Urology (Vol. 181, pp.1104-13), Thalidomide may be effective for the treatment of men who [...]